Who Paid My Doc
Mary Beth McGann
Sleep Medicine Shreveport, LA Medical Doctor
NPI 1477565323 CMS profile 775445
7607 Fern Ave Ste 204D, Shreveport, LA 71105
General payments
$234
Research payments
$0
Ownership & investment interest
$0
Through program year 2020, Mary Beth McGann of Shreveport, LA is reported in the CMS Open Payments database as having received $234 across 2 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 27th percentile of Sleep Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2020 | General | $234 | 2 |
Beside peers
- Mary Beth McGann
- Sleep Medicine median
- Middle half of Sleep Medicine
- National median
In program year 2025, general payments to Mary Beth McGann were reported at $0. Among 263 Sleep Medicine profiles paid that year, the median was $337 and the middle half received between $114 and $1,241.
Show as a table
| Year | Mary Beth McGann | Sleep Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $206 | $79–$855 | $163 |
| 2020 | $234 | $170 | $48–$1,437 | $114 |
| 2021 | $0 | $178 | $53–$1,297 | $132 |
| 2022 | $0 | $313 | $95–$1,332 | $149 |
| 2023 | $0 | $307 | $117–$1,081 | $160 |
| 2024 | $0 | $308 | $100–$1,432 | $164 |
| 2025 | $0 | $337 | $114–$1,241 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 10 drugsPart D claims
216
Drug cost
$7,365
Branded share of claims
39.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Pristiq Desvenlafaxine Succinate | Brand | 11 | $4,261 | |
| Venlafaxine Hcl Er Venlafaxine Hcl | Brand | 20 | $710 | |
| Bupropion Xl Bupropion Hcl | Brand | 41 | $617 | |
| Aripiprazole | Generic | 19 | $481 | |
| Fluoxetine Hcl | Generic | 27 | $393 | |
| Escitalopram Oxalate | Generic | 16 | $272 | |
| Bupropion Hcl Sr Bupropion Hcl | Brand | 13 | $237 | |
| Clonazepam | Generic | 35 | $163 | |
| Eszopiclone | Generic | 13 | $142 | |
| Alprazolam | Generic | 21 | $90 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Sleep Medicine in Louisiana
Related records
Sleep Medicine in Louisiana
Practitioners in the same specialty and state, ranked by reported value.
All Sleep Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Louisiana
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.